Conditions: Carcinoma, Non Small Cell Lung
Keywords: non-small cell lung cancer advanced previously treated
Allocation: NON_RANDOMIZED | Intervention model: 
Enrollment: 66
Healthy volunteers: no

Brief summary:
To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.

Detailed description:

Arms:
arm 1: descriptive: adenocarcinoma histology arm 2: descriptive: non-adenocarcinoma histology

Interventions: intervention 1: PF-00299804 intervention 2: PF-00299804
Intervention descriptions: intervention 1: PF-00299804 orally at 45 mg daily, on continuous schedule intervention 2: PF-00299804 orally at 45 mg daily, on continuous schedule

Protocol document: